Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.
What happened
FDA inspected Columbia Cosmetics Manufacturing Inc.'s drug manufacturing facility from April 7 to 14, 2025. FDA found significant CGMP violations for OTC sunscreen drug products, including inadequate out-of-specification investigations, release of subpotent product, missing identity testing for high-risk components such as glycerin, and unvalidated manufacturing processes. FDA also said the firm's quality system was ineffective.
What FDA found
The firm did not thoroughly investigate out-of-specification results and released subpotent sunscreen drug product without adequate quality group review.
21 CFR 211.192The firm did not perform adequate identity testing on each incoming component lot, including glycerin at risk for diethylene glycol or ethylene glycol contamination, and did not establish the reliability of supplier certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm manufactured OTC sunscreen drug products without adequate validation of its manufacturing processes.
21 CFR 211.100(a)The firm's quality group was not enabled to exercise proper authority or did not sufficiently implement its responsibilities.
21 CFR parts 210 and 211
What FDA wants
FDA asks Columbia to correct the violations promptly and respond in writing within 15 working days with corrective actions, including a retrospective out-of-specification review, diethylene glycol/ethylene glycol testing and risk assessment, process validation, and quality-system remediation. FDA also recommends a qualified current good manufacturing practice consultant.
Who should pay attention
- brands that buy OTC sunscreens from this contract manufacturer
- companies relying on supplier certificates of analysis for high-risk ingredients
- contract manufacturers making OTC drug products
This is a summary. Read the original letter on fda.gov.